WQ-3034 is a newly synthesized acidic
fluoroquinolone. We assessed its in vitro activity against Mycobacterium tuberculosis and M. avium complex using
levofloxacin (LVFX),
ciprofloxacin (CPFX),
sparfloxacin (SPFX), and
KRM-1648 (KRM) as reference drugs. The MICs of these agents were determined by the
agar dilution method with 7H11 medium. The MICs at which 50 and 90% of the test strains were inhibited (MIC(50)s, and MIC(90)s, respectively) for the test
quinolones for
rifampin (RMP)-susceptible M.
tuberculosis strains were in the order SPFX < LVFX </=
WQ-3034 </= CPFX, while those for RMP-resistant M.
tuberculosis strains were in the order SPFX </=
WQ-3034 </= LVFX < CPFX. The MICs of KRM for RMP-susceptible M.
tuberculosis were much lower than those of the test
quinolones, while the MIC(90) of KRM for RMP-resistant M.
tuberculosis strains was higher than those of the
quinolones. The MIC(50)s and MIC(90)s of the test drugs for M. avium were in the order KRM < SPFX < CPFX </=
WQ-3034 </= LVFX, while those for M. intracellulare were in the order KRM < SPFX <
WQ-3034 LVFX </= CPFX. Next, we compared the antimicrobial activities of the test drugs against M.
tuberculosis organisms residing in cells of the Mono Mac 6 macrophage (Mphi)-like cell line (MM6-Mphis) and of the A-549 type II alveolar cell line (A-549 cells). When drugs were added at the concentration that achieves the maximum concentration in blood, progressive killing or inhibition of the M.
tuberculosis organisms residing in MM6-Mphis and A-549 cells was observed in the order KRM > SPFX >/= LVFX >
WQ-3034 > CPFX. The efficacies of all
quinolones against intracellular M.
tuberculosis organisms were significantly lower in A-549 cells than in MM6-Mphis.
WQ-3034 at the MIC caused more marked growth inhibition of intramacrophage M.
tuberculosis than did LVFX. These findings indicate that the in vitro anti-M.
tuberculosis activity of
WQ-3034 is greater than that of CPFX and is comparable to that of LVFX.